# Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)

> **NCT04637555** · PHASE3 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Post Myocardial Infarction

## Interventions

- **DRUG:** sacubitril/valsartan

## Key facts

- **NCT ID:** NCT04637555
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05-26
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** CLCZ696G2301E1 extension study did not start as the core study (CLCZ696G2301) did not meet the primary endpoint.
- **Last updated:** 2021-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04637555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04637555, "Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04637555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*